Post patent how will yervoy's market share change?

When does Yervoy lose exclusivity?

Yervoy’s composition-of-matter patent expired in 2021. The last remaining U.S. market protections ended in 2023, opening the door for biosimilar competition starting in 2025.

Who is developing Yervoy biosimilars?

Several companies have active programs. Henlius, Bio-Thera, and Celltrion have announced phase-III trials or regulatory filings, while large generic firms such as Sandoz and Mylan are also evaluating entry.

How will pricing change after patent expiry?

List prices for Yervoy currently exceed $15,000 per dose. Analysts expect the first biosimilars to launch 15-30% below that level, with deeper cuts possible once two or three competitors reach the market.

How will Bristol-Myers Squibb defend its position?

BMS is shifting Yervoy into earlier treatment lines, pairing it with nivolumab in adjuvant and perioperative settings. The company is also exploring new fixed-dose regimens and subcutaneous formulations to retain share even after price erosion.

What share do analysts expect biosimilars to capture?

Forecasts from major investment banks project biosimilar penetration of 25-40% within three years of launch, depending on payer coverage and physician comfort with switching. BMS is assumed to retain the majority share in the first two years because of brand loyalty and entrenched use in combination regimens.

How do regulatory and reimbursement dynamics affect uptake?

Medicare Part B and many commercial plans are expected to place biosimilars on preferred tiers, but some oncology pathways still require step edits or prior authorization that favor the originator. Real-world switching rates will depend on these formulary decisions.

What role will clinical data play in physician choice?

Oncologists cite a need for head-to-head switching studies and long-term safety data. Until such evidence accumulates, uptake is likely to remain gradual and concentrated in cost-sensitive accounts.

How will combination regimens change market dynamics?

Yervoy is rarely used alone. As nivolumab biosimilars also enter, hospitals may adopt “all-biosimilar” bundles, accelerating erosion for both products. Conversely, new clinical trials pairing Yervoy with non-checkpoint agents could create protected niches for the branded product.

DrugPatentWatch.com